WO2014195850A3 - Compositions and methods for the treatment of neurologic diseases and neurological disorders - Google Patents

Compositions and methods for the treatment of neurologic diseases and neurological disorders Download PDF

Info

Publication number
WO2014195850A3
WO2014195850A3 PCT/IB2014/061893 IB2014061893W WO2014195850A3 WO 2014195850 A3 WO2014195850 A3 WO 2014195850A3 IB 2014061893 W IB2014061893 W IB 2014061893W WO 2014195850 A3 WO2014195850 A3 WO 2014195850A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
treatment
compositions
methods
neurological disorders
Prior art date
Application number
PCT/IB2014/061893
Other languages
French (fr)
Other versions
WO2014195850A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Publication of WO2014195850A2 publication Critical patent/WO2014195850A2/en
Publication of WO2014195850A3 publication Critical patent/WO2014195850A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for the treatment of neurologic diseases and neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, diabetic neuropathy, seizures, creutzfeld-jacob disease, multiple sclerosis, back pain, parkinson's, obesity, bipolar depression, partial-onset seizures.
PCT/IB2014/061893 2013-06-05 2014-06-02 Compositions and methods for the treatment of neurologic diseases and neurological disorders WO2014195850A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2465CH2013 2013-06-05
IN2465/CHE/2013 2013-06-05

Publications (2)

Publication Number Publication Date
WO2014195850A2 WO2014195850A2 (en) 2014-12-11
WO2014195850A3 true WO2014195850A3 (en) 2015-05-21

Family

ID=52008664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/061893 WO2014195850A2 (en) 2013-06-05 2014-06-02 Compositions and methods for the treatment of neurologic diseases and neurological disorders

Country Status (1)

Country Link
WO (1) WO2014195850A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505776B2 (en) 2013-03-14 2016-11-29 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
EP3110793B1 (en) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037133A1 (en) * 2004-09-29 2006-04-06 Ceptor Corporation Treatment of traumatic or degenerative neurologic, otologic, or ophthalmologic diseases with targeted protease inhibitors
US8017581B1 (en) * 2004-05-11 2011-09-13 Centre National De La Recherche Scientifique (Cnrs) MSH-agonist tripeptide conjugates
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2013027150A1 (en) * 2011-08-21 2013-02-28 Mahesh Kandula Compositions and methods for the treatment of parkinson's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017581B1 (en) * 2004-05-11 2011-09-13 Centre National De La Recherche Scientifique (Cnrs) MSH-agonist tripeptide conjugates
WO2006037133A1 (en) * 2004-09-29 2006-04-06 Ceptor Corporation Treatment of traumatic or degenerative neurologic, otologic, or ophthalmologic diseases with targeted protease inhibitors
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2013027150A1 (en) * 2011-08-21 2013-02-28 Mahesh Kandula Compositions and methods for the treatment of parkinson's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505776B2 (en) 2013-03-14 2016-11-29 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases

Also Published As

Publication number Publication date
WO2014195850A2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
MX2019007713A (en) Compositions and methods for the treatment of chronic pain.
MX2021010046A (en) A new therapeutical composition containing apomorphine as active ingredient.
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
SG10201907291QA (en) Monomethylfumarate prodrug compositions
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
MX2019006163A (en) Compositions and methods for the treatment of oral infectious diseases.
WO2013167998A3 (en) Compositions and methods for the treatment of autonomic and other neurological disorders
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2013167984A3 (en) Compositions and methods for the treatment of muscle pain
WO2017208088A3 (en) Compositions and methods for the treatment of parkinson's disease
WO2014122621A3 (en) Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation
MX2021005442A (en) Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases.

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14808431

Country of ref document: EP

Kind code of ref document: A2